
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is a well-established biopharmaceutical company, with a strong portfolio of treatments for neurodegenerative and rare diseases. While its multiple sclerosis franchise is declining, it still accounts for a significant portion of revenue and has opportunities for growth through its partnership with Roche. Biogen also has several promising pipeline programs, with upcoming readouts for felzartamab and litifilimab that could have a positive impact on its revenue and investor interest. While there are risks, we believe Biogen's commitment to its community and potential for pipeline success make it a favorable investment opportunity.
Bears say
Biogen is heavily reliant on its multiple sclerosis franchise, which is in decline, and its CD20 collaboration agreements, which contribute a significant portion of its revenue. Its newer franchises are promising, but carry higher risk. The company's pipeline looks poised to deliver diversification, but there are also significant unknowns and limitations in the upcoming readouts. Additional costs associated with their recent acquisition may require disciplined capital allocation. The potential for significant market opportunity in Alzheimer's and modest credit given to the pipeline could drive enthusiasm, but it is not fully reflected in the current valuation and carries significant risk.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares